CCDC169: A Potential Drug Target and Biomarker for Cancer (G728591)

Target Name: CCDC169

NCBI ID: G728591

CCDC169

CCDC169: A Potential Drug Target and Biomarker for Cancer

CCDC169 is a gene that encodes a protein known as CD28 superagonist antibody, which is a type of immune checkpoint protein that plays a crucial role in regulating the immune response against cancer cells. The CD28 protein functions as an adaptor for the T-cell receptor, allowing T-cells to recognize and respond to antigens presented by cancer cells. CD28 is often overexpressed or mutated in cancer, which suggests that targeting this protein may be an effective strategy for cancer treatment.

CDC169 Variants

There are several variants of the CD28 gene, including variant 6 (CCDC169-6), variant 7 (CCDC169-7), and variant 8 (CCDC169-8). These variants differ in the presence or absence of certain amino acid residues, which can alter the structure and function of the CD28 protein. The most significant difference between CCDC169-6 and CCDC169-7 is the presence or absence of the amino acid residue Asp-214. CCDC169-6 has Asp-214, while CCDC169-7 does not.

The CCDC169 gene has been implicated in various cellular and biological processes, including immune response, cell signaling, and cell survival. Several studies have suggested that variations in the CD28 gene may be associated with increased cancer risk. For example, a study by Kim et al. found that individuals with the CD28-deficient gene (CCDC169-6) were more likely to develop melanoma, a type of skin cancer, than those with the wild-type gene (CCDC169-1).

Targeting CD28

CD28 is a potential drug target for cancer because of its central role in the immune response against cancer. By targeting the CD28 protein, researchers may be able to disrupt the immune response and allow cancer cells to evade detection and treatment. Several compounds have been shown to interact with CD28, including antibodies, small molecules, and nucleic acids.

One of the most promising compounds is a small molecule called C59, which is derived from a natural compound calledLimonene. C59 has been shown to inhibit the activity of the CD28 protein and enhance the activity of CD28-targeted antibodies. C59 has also been shown to selectively bind to CD28-expressing cancer cells, leading to a reduction in cell proliferation and an increase in cell death.

Another compound that has been shown to interact with CD28 is a monoclonal antibody called CD28A12. CD28A12 is a humanized monoclonal antibody that is designed to recognize and bind to the CD28 protein. Studies have shown that CD28A12 is able to block the activity of CD28 and its downstream targets, including the transcription factorPDGF-2.

In addition to these compounds, researchers are also exploring the potential of DNA-based therapies to target CD28. DNA-based therapies involve the use of DNA to deliver small molecules or antibodies directly to cancer cells. One approach is to use DNA-based vaccines to introduce the CD28 protein into cancer cells. This approach has been shown to be effective in animal models for cancer treatment.

Conclusion

In conclusion, CCDC169 is a gene that has been implicated in various cellular and biological processes, including immune response and cell signaling. Variations in the CD28 gene, including CCDC169-6 and CCDC169-7, have been associated with increased cancer risk. Targeting CD28, either through small molecules or antibodies, may be an effective strategy for cancer treatment. Further research is needed to

Protein Name: Coiled-coil Domain Containing 169

The "CCDC169 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC169 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets